LEXARIA BIOSCIENCE CORP. Revenue from Contract with Customer, Excluding Assessed Tax
LEXARIA BIOSCIENCE CORP. (LEXX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $183.92 thousand for the 3-month period ending 2024-11-30, per its 10-Q filed 2025-01-10.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-01-10
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-11-30 was $183.92K, a 21.58% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-08-31 was $84.00K, a 173.25% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-05-31 was $84.00K, a 8.10% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-02-29 was $145.00K, a 624.09% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $464.28K, a 105.24% increase from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $226.21K, a 11.43% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $255.40K, a 64.66% decline from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $722.74K, a 87.95% increase from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2024-11-30 | $183.92K 10-Q · filed 2025-01-10 | $267.92K derived: sum of 2 quarters · filed 2025-01-10 | $351.92K derived: sum of 3 quarters · filed 2025-01-10 | $496.92K derived: sum of 4 quarters · filed 2025-01-10 | |||
| 2024-08-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $168.00K derived: sum of 2 quarters · filed 2024-11-26 | $313.00K derived: sum of 3 quarters · filed 2024-11-26 | $464.28K 10-K · filed 2024-11-26 | |||
| 2024-05-31 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | $229.00K derived: sum of 2 quarters · filed 2024-07-12 | $380.28K 10-Q · filed 2024-07-12 | $411.02K derived: sum of 4 quarters · filed 2025-01-10 | |||
| 2024-02-29 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-04-09 | $296.28K 10-Q · filed 2024-04-09 | $327.02K derived: sum of 3 quarters · filed 2025-01-10 | $404.73K derived: sum of 4 quarters · filed 2025-01-10 | |||
| 2023-11-30 | $151.28K 10-Q · filed 2025-01-10 | $182.02K derived: sum of 2 quarters · filed 2025-01-10 | $259.73K derived: sum of 3 quarters · filed 2025-01-10 | $279.75K derived: sum of 4 quarters · filed 2025-01-10 | |||
| 2023-08-31 | $30.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $108.45K derived: sum of 2 quarters · filed 2024-11-26 | $128.47K derived: sum of 3 quarters · filed 2024-11-26 | $226.21K 10-K · filed 2024-11-26 | |||
| 2023-05-31 | $77.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | $97.73K derived: sum of 2 quarters · filed 2024-07-12 | $195.47K 10-Q · filed 2024-07-12 | $229.64K 10-Q · filed 2023-07-14 | $306.62K derived: sum of 4 quarters · filed 2024-07-12 | ||
| 2023-02-28 | $20.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-04-09 | $117.76K 10-Q · filed 2024-04-09 | $136.49K 10-Q · filed 2023-04-14 | $228.91K derived: sum of 3 quarters · filed 2024-04-09 | $328.63K derived: sum of 4 quarters · filed 2024-04-09 | ||
| 2022-11-30 | $97.73K 10-Q · filed 2024-01-12 | $101.48K 10-Q · filed 2023-01-17 | $208.88K derived: sum of 2 quarters · filed 2024-01-12 | $308.60K derived: sum of 3 quarters · filed 2024-01-12 | $339.25K derived: sum of 4 quarters · filed 2024-01-12 | ||
| 2022-08-31 | $111.15K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $210.87K derived: sum of 2 quarters · filed 2023-11-20 | $241.52K derived: sum of 3 quarters · filed 2023-11-20 | $255.40K 10-K · filed 2023-11-20 | |||
| 2022-05-31 | $99.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | $130.37K derived: sum of 2 quarters · filed 2023-07-14 | $144.25K 10-Q · filed 2023-07-14 | $175.27K derived: sum of 4 quarters · filed 2023-07-14 | |||
| 2022-02-28 | $30.65K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-04-14 | $44.53K 10-Q · filed 2023-04-14 | $75.55K derived: sum of 3 quarters · filed 2023-04-14 | $279.61K derived: sum of 4 quarters · filed 2023-04-14 | |||
| 2021-11-30 | $13.88K 10-Q/A · filed 2023-01-18 | $44.90K derived: sum of 2 quarters · filed 2023-01-18 | $248.96K derived: sum of 3 quarters · filed 2023-01-18 | $440.96K derived: sum of 4 quarters · filed 2023-01-18 | |||
| 2021-08-31 | $31.02K derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $235.08K derived: sum of 2 quarters · filed 2022-11-28 | $427.08K derived: sum of 3 quarters · filed 2022-11-28 | $722.74K 10-K · filed 2022-11-28 | |||
| 2021-05-31 | $204.06K 10-Q · filed 2021-07-15 | $396.06K derived: sum of 2 quarters · filed 2021-07-15 | $691.72K 10-Q · filed 2022-07-14 | $825.46K derived: sum of 4 quarters · filed 2021-07-15 | |||
| 2021-02-28 | $192.01K 10-Q · filed 2021-04-14 | $487.66K 10-Q · filed 2021-04-14 | $621.40K derived: sum of 3 quarters · filed 2021-04-14 | $657.82K derived: sum of 4 quarters · filed 2021-07-15 | |||
| 2020-11-30 | $295.66K 10-Q · filed 2021-01-14 | $429.39K derived: sum of 2 quarters · filed 2021-01-14 | $465.82K derived: sum of 3 quarters · filed 2021-07-15 | $503.37K derived: sum of 4 quarters · filed 2021-07-15 | |||
| 2020-08-31 | $133.74K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-15 | $170.16K derived: sum of 2 quarters · filed 2021-07-15 | $207.71K derived: sum of 3 quarters · filed 2021-07-15 | $384.54K 10-K · filed 2020-10-15 | |||
| 2020-05-31 | $36.42K 10-Q · filed 2021-07-15 | $81.42K 10-Q · filed 2020-06-29 | $73.97K derived: sum of 2 quarters · filed 2021-07-15 | $250.80K 10-Q · filed 2021-07-15 | $209.43K derived: sum of 4 quarters · filed 2021-07-15 | ||
| 2020-02-29 | $37.55K 10-Q · filed 2021-04-14 | $107.30K 10-Q · filed 2020-04-03 | $99.63K 10-Q · filed 2021-04-14 | $169.38K 10-Q · filed 2020-04-03 | $173.00K derived: sum of 3 quarters · filed 2021-04-14 | $232.93K derived: sum of 4 quarters · filed 2021-04-14 | |
| 2019-11-30 | $10.33K 10-Q · filed 2021-01-14 | $62.08K 10-Q · filed 2020-01-09 | $135.45K derived: sum of 2 quarters · filed 2021-01-14 | $195.38K derived: sum of 3 quarters · filed 2021-01-14 | $210.73K derived: sum of 4 quarters · filed 2021-01-14 | ||
| 2019-08-31 | $125.12K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-15 | $185.05K derived: sum of 2 quarters · filed 2020-10-15 | $200.40K derived: sum of 3 quarters · filed 2020-10-15 | $222.61K 10-K · filed 2020-10-15 | |||
| 2019-05-31 | $59.93K 10-Q · filed 2020-06-29 | $75.28K derived: sum of 2 quarters · filed 2020-06-29 | $97.49K 10-Q · filed 2020-06-29 | $193.84K derived: sum of 4 quarters · filed 2020-06-29 | |||
| 2019-02-28 | $15.35K 10-Q · filed 2020-04-03 | $37.56K 10-Q · filed 2020-04-03 | $133.91K derived: sum of 3 quarters · filed 2020-04-03 | $274.25K derived: sum of 4 quarters · filed 2020-04-03 | |||
| 2018-11-30 | $22.21K 10-Q · filed 2020-01-09 | $118.56K derived: sum of 2 quarters · filed 2020-01-09 | $258.90K derived: sum of 3 quarters · filed 2020-01-09 | $430.86K derived: sum of 4 quarters · filed 2020-01-09 | |||
| 2018-08-31 | $96.35K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-14 | $236.69K derived: sum of 2 quarters · filed 2019-11-14 | $408.65K derived: sum of 3 quarters · filed 2019-11-14 | $433.29K 10-K · filed 2019-11-14 | |||
| 2018-05-31 | $140.34K 10-Q · filed 2019-07-08 | $312.30K derived: sum of 2 quarters · filed 2019-07-08 | $336.93K 10-Q · filed 2019-07-08 | ||||
| 2018-02-28 | $171.96K 10-Q · filed 2019-04-15 | $196.59K 10-Q · filed 2019-04-15 | |||||
| 2017-11-30 | $24.64K 10-Q · filed 2019-01-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |